Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. The company has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. The company also offers VivaGel BV and VivaGel Condom products.
Follow-Up Questions
Who is the CEO of Starpharma Holdings Ltd?
Ms. Cheryl Maley is the Chief Executive Officer of Starpharma Holdings Ltd, joining the firm since 2024.
What is the price performance of SPHRY stock?
The current price of SPHRY is $2.4, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Starpharma Holdings Ltd?
Starpharma Holdings Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Starpharma Holdings Ltd market cap?
Starpharma Holdings Ltd's current market cap is $100.3M
Is Starpharma Holdings Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Starpharma Holdings Ltd, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
